Manmeet Ahluwalia MD, FACP, MBA
Deputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, FloridaDr. Manmeet Ahluwalia is the Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, Ohio, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
A neuro-oncologist, Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.
Recent Contributions to PracticeUpdate:
- Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
- ASTRO Guidelines on Radiation Therapy for Brain Metastases
- The End-of-the-Road for Immunotherapies in GBM or New Opportunities for More Nuanced/aggressive Approaches? CheckMate 498
- Radiotherapy Plus Nivolumab or Temozolomide for Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
- A Preface to the Brain Metastases Articles in This Week in Brain Cancer
- Ruxolitinib Plus Radiation and Temozolomide for Newly Diagnosed Grade III Gliomas and Glioblastoma
- Nivolumab Plus Bevacizumab for Recurrent Glioblastoma
- VT1021 for Recurrent Glioblastoma
- Predicting Outcomes for Patients With Glioblastoma Using Cellworks Singula
- BRAF/MEK Inhibition Among Patients With Papillary Craniopharyngiomas